Abstract
The single-dose pharmacokinetics of cefsulodin were evaluated in 12 patients with cystic fibrosis. Each patient received 3 g of cefsulodin intravenously over 30 min. Multiple plasma and urine samples were obtained during the 6-h study period for the determination of cefsulodin. Pharmacokinetic parameters were determined by model-independent methods. Mean values for t1/2, Vss, and CLp were 1.53 h, 0.242 liters/kg, and 117.3 ml/min per 1.73 m2, respectively. Six-hour urine recovery revealed 73.2% of the administered dose with a corresponding cefsulodin urinary clearance of 75.1 ml/min. These pharmacokinetic data in patients with cystic fibrosis appear consistent with data reported for unaffected individuals.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Arvidsson A., Alván G., Strandvik B. Difference in renal handling of cefsulodin between patients with cystic fibrosis and normal subjects. Acta Paediatr Scand. 1983 Mar;72(2):293–294. doi: 10.1111/j.1651-2227.1983.tb09715.x. [DOI] [PubMed] [Google Scholar]
- Gibaldi M., Koup J. R. Pharmacokinetic concepts - drug binding, apparent volume of distribution and clearance. Eur J Clin Pharmacol. 1981;20(4):299–305. doi: 10.1007/BF00618781. [DOI] [PubMed] [Google Scholar]
- Gibson T. P., Granneman G. R., Kallal J. E., Sennello L. T. Cefsulodin kinetics in renal impairment. Clin Pharmacol Ther. 1982 May;31(5):602–608. doi: 10.1038/clpt.1982.84. [DOI] [PubMed] [Google Scholar]
- Granneman G. R., Sennello L. T. Precise high-performance liquid chromatographic procedure for the determination of cefsulodin, a new antipseudomonal cephalosporin antibiotic, in plasma. J Pharm Sci. 1982 Oct;71(10):1112–1115. doi: 10.1002/jps.2600711008. [DOI] [PubMed] [Google Scholar]
- Granneman G. R., Sennello L. T., Sonders R. C., Wynne B., Thomas E. W. Cefsulodin kinetics in healthy subjects after intramuscular and intravenous injection. Clin Pharmacol Ther. 1982 Jan;31(1):95–103. doi: 10.1038/clpt.1982.15. [DOI] [PubMed] [Google Scholar]
- Kearns G. L., Hilman B. C., Wilson J. T. Dosing implications of altered gentamicin disposition in patients with cystic fibrosis. J Pediatr. 1982 Feb;100(2):312–318. doi: 10.1016/s0022-3476(82)80663-x. [DOI] [PubMed] [Google Scholar]
- Kelly H. B., Menendez R., Fan L., Murphy S. Pharmacokinetics of tobramycin in cystic fibrosis. J Pediatr. 1982 Feb;100(2):318–321. doi: 10.1016/s0022-3476(82)80664-1. [DOI] [PubMed] [Google Scholar]
- Kercsmar C. M., Stern R. C., Reed M. D., Myers C. M., Murdell D., Blumer J. L. Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):289–295. doi: 10.1093/jac/12.suppl_a.289. [DOI] [PubMed] [Google Scholar]
- Kondo M., Tsuchiya K. Comparative in vivo activities of cefsulodin, sulbenicillin, and gentamicin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1978 Jul;14(1):151–153. doi: 10.1128/aac.14.1.151. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Matzke G. R., Keane W. F. Cefsulodin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother. 1983 Mar;23(3):369–373. doi: 10.1128/aac.23.3.369. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Yaffe S. J., Gerbracht L. M., Mosovich L. L., Mattar M. E., Danish M., Jusko W. J. Pharmacokinetics of methicillin in patients with cystic fibrosis. J Infect Dis. 1977 May;135(5):828–831. doi: 10.1093/infdis/135.5.828. [DOI] [PubMed] [Google Scholar]